Progression to hepatitis and fibrosis secondary to lomitapide use--reply

JAMA Intern Med. 2014 Sep;174(9):1522-3. doi: 10.1001/jamainternmed.2014.1528.

Authors

Frank M Sacks¹, Maxine Stanesa², Robert A Hegele³

Affiliations

¹ Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts2Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, Massachusetts3Harvard Medical School, Boston, Massachusetts.
² Harvard Vanguard Medical Associates, Boston, Massachusetts.
³ Robarts Research Institute, London, Ontario, Canada.

PMID: 25178869
DOI: 10.1001/jamainternmed.2014.1528

No abstract available

Publication types

Letter
Comment

MeSH terms

Anticholesteremic Agents / therapeutic use*
Benzimidazoles / therapeutic use*
Female
Humans
Hypertriglyceridemia / complications*
Hypertriglyceridemia / drug therapy*
Pancreatitis, Chronic / drug therapy*
Pregnancy

Substances

Anticholesteremic Agents
Benzimidazoles